financetom
Business
financetom
/
Business
/
Kishore Biyani's Future Enterprises defers board meeting to September 7
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kishore Biyani's Future Enterprises defers board meeting to September 7
Aug 28, 2020 11:40 PM

Kishore Biyani-led Future Enterprises has pushed its board meeting to September 7. Earlier, the board was scheduled to meet on Friday for consideration and approval of audited financial results of the company for the fiscal ending March 2020.

Share Market Live

NSE

The meeting has been deferred due to non-completion of audit process of financial results, the company said in a late evening announcement.

The company further said that trading window for dealing in the securities of the company, which was already closed w.e.f. April 1, 2020, will remain closed till 48 hours after the announcement of audited financial results.

Future Retail, one of the operating companies of Future Group, recently averted a default by making an interest payment of $14 million or about Rs 105 crore to its coupon holders for $500 million senior secured notes. The company was originally due to make the interest payment on its 5.60 percent 2025 dollar notes on July 22 which it missed.

Future Group had a consolidated debt of Rs 12,778 crore as of September 2019, as per the company’s public records. Its flagship company Future Retail had a gross debt of Rs 2,657 crore.

First Published:Aug 29, 2020 8:40 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Says FDA Granted Priority Review on Keytruda, Keytruda Qlex Applications for Bladder Cancer
Merck Says FDA Granted Priority Review on Keytruda, Keytruda Qlex Applications for Bladder Cancer
Oct 23, 2025
08:47 AM EDT, 10/23/2025 (MT Newswires) -- Merck ( MRK ) said Thursday the US Food and Drug Administration granted priority review for two supplemental biologics license applications for Keytruda and Keytruda Qlex, each used with Padcev, to treat patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy. The company said the regulator set an action date of April...
BRIEF-Piper Sandler Announces Acquisition to Strengthen Presence in the Middle East
BRIEF-Piper Sandler Announces Acquisition to Strengthen Presence in the Middle East
Oct 23, 2025
Oct 23 (Reuters) - Piper Sandler Companies ( PIPR ): * PIPER SANDLER ANNOUNCES ACQUISITION TO STRENGTHEN PRESENCE IN THE MIDDLE EAST * PIPER SANDLER ( PIPR ) - TO BUY MENA GROWTH PARTNERS Source text: Further company coverage: ...
Integer's Fiscal Q3 Adjusted Earnings, Revenue Rise; Narrows 2025 Guidance
Integer's Fiscal Q3 Adjusted Earnings, Revenue Rise; Narrows 2025 Guidance
Oct 23, 2025
08:46 AM EDT, 10/23/2025 (MT Newswires) -- Integer (ITGR) reported fiscal Q3 adjusted earnings Thursday of $1.79 per diluted share, compared with $1.43 a year earlier. Analysts surveyed by FactSet expected $1.68. Sales for the quarter ended Sept. 26 were $467.7 million, compared with $431.4 million a year earlier. Analysts surveyed by FactSet expected $466.4 million. The company narrowed its...
Form 8.3 - Alpha Group International PLC
Form 8.3 - Alpha Group International PLC
Oct 23, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved